TY - JOUR

T1 - Update on nephrogenic systemic fibrosis

AU - Marckmann, P.

AU - Logager, V.B.

AU - Thomsen, Henrik S.

PY - 2008

Y1 - 2008

N2 - Gadolinium-based contrast agents were for many years considered safe, but this is no longer the case. The least stable agents may trigger the development of nephrogenic systemic fibrosis (NSF), a generalized fibrotic disorder, in renal failure patients. The use of gadodiamide and gadopentetate dimeglumine is now contraindicated in Europe and Japan in patients who have a glomerular filtration rate less than 30 mL/min/1.73 m(2), including those on dialysis. The fear of NSF, however, should not lead to an enhanced MR imaging examination being denied when there is a good clinical indication to give a gadolinium-based contrast agent Udgivelsesdato: 2008/11

AB - Gadolinium-based contrast agents were for many years considered safe, but this is no longer the case. The least stable agents may trigger the development of nephrogenic systemic fibrosis (NSF), a generalized fibrotic disorder, in renal failure patients. The use of gadodiamide and gadopentetate dimeglumine is now contraindicated in Europe and Japan in patients who have a glomerular filtration rate less than 30 mL/min/1.73 m(2), including those on dialysis. The fear of NSF, however, should not lead to an enhanced MR imaging examination being denied when there is a good clinical indication to give a gadolinium-based contrast agent Udgivelsesdato: 2008/11

M3 - Journal article

VL - 16

SP - 551-60, vii

JO - Magnetic Resonance Imaging Clinics of North America

JF - Magnetic Resonance Imaging Clinics of North America

SN - 1064-9689

IS - 4

ER -